Presenting results of probabilistic sensitivity analysis: The incremental benefit curve

Health Economics

Volumn 17, Issue 3, 2008, Pages 435-440

  Bala, Mohan V ^a   Zarkin, Gary A ^b   Mauskopf, Josephine ^c  

^a CENTOCOR INC   (United States)

^b RTI INTERNATIONAL   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cost effectiveness analysis; Risk; Uncertainty

Indexed keywords

DRUG;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SOCIAL WELFARE;

COST-BENEFIT ANALYSIS; HUMANS; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT;

EID: 41049083144     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1274     Document Type: Article

References (13)

1. Arrow K, Lind R. 1970. Uncertainty and the evaluation of public intervention decisions. American Economic Review 60: 364-378.
2. Bala MV, Mauskopf JO. 1999. The estimation and use of confidence intervals in economic analysis. Drug Information Journal 33(3): 841-848.
3. Bala MV, Zarkin GA. 2002. Application of cost-effectiveness analysis to multiple products: a practical guide. American Journal of Managed Care 8(3): 211-218.
4. Bala MV, Zarkin GA, Mauskopf JA. 2002. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. Value Health 5(4): 338-346.
5. Claxton K. 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18(3): 341-364.
6. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T. 2005. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 14(4): 339-347.
7. Fenwick E, Claxton K, Sculpher M. 2001. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 10(8): 779-787.
8. Graff Zivin J. 2001. Cost-effectiveness analysis with risk aversion. Health Economics 10(6): 499-508.
9. Graff Zivin J, Bridges J. 2002. Addressing risk preferences in cost-effectiveness analyses. Applied Health Economics and Health Policy 1(3): 135-139.
10. Laska EM, Meisner M, Siegel C, Stinnett AA. 1999. Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimality and equivalence. Health Economics 8(2): 171-174.
11. Lothgren M, Zethraeus N. 2000. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 9(7): 623-630.
12. O'Hagan A, Stevens JW, Montmartin J. 2000. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 17(4): 339-349 (Review).
13. Stinnett AA, Mullahy J. 1998. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 18(2 Suppl.): S68-S80.